ArticleCancers2022
A Real-World Systematic Analysis of Driver Mutations' Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Real-World Treatment Patterns and Survival in Patients withCurrent oncology (Toronto, Ont.) · 2026Observational
- Review
- Actionable driver gene alterations in early-stage non-small cell lung cancer: a review.Therapeutic advances in medical oncology · 2026Review
- Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2025Review
- Living on the edge: Role of adjuvant therapy after resection of primary lung cancer within 2 millimeters of a T-stage cutoff.The Journal of thoracic and cardiovascular surgery · 2025Article
- Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study.Future oncology (London, England) · 2025Article
- Real-world biomarker testing patterns: clinical-pathological portrait of early and late non-small cell lung cancer in hub and spoke North Italian centers.Translational lung cancer research · 2024Article
- Article
- Real-World Evidence Study of Patients withCurrent oncology (Toronto, Ont.) · 2024Article
- Could the molecular profile aid in predicting occult nodal metastasis in early-stage lung adenocarcinoma?Surgery today · 2024Article
- Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.The Lancet regional health. Europe · 2024Review
- Analysis of predictive factors of unforeseen nodal metastases in resected clinical stage I NSCLC.Frontiers in oncology · 2023Article
- Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)-A Single Center, Retrospective Observational Study.International journal of molecular sciences · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The approval of osimertinib for adjuvant treatment of stage I-II-III
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.